JP2020502224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502224A5 JP2020502224A5 JP2019533666A JP2019533666A JP2020502224A5 JP 2020502224 A5 JP2020502224 A5 JP 2020502224A5 JP 2019533666 A JP2019533666 A JP 2019533666A JP 2019533666 A JP2019533666 A JP 2019533666A JP 2020502224 A5 JP2020502224 A5 JP 2020502224A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- crystalline form
- purity
- composition according
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 31
- 239000000203 mixture Substances 0.000 claims 15
- -1 Pyrimidine-4-yl Chemical group 0.000 claims 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022207814A JP2023024729A (ja) | 2016-12-21 | 2022-12-26 | ヤヌスキナーゼ阻害剤の結晶形 |
| JP2024134769A JP2024161449A (ja) | 2016-12-21 | 2024-08-13 | ヤヌスキナーゼ阻害剤の結晶形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437262P | 2016-12-21 | 2016-12-21 | |
| US62/437,262 | 2016-12-21 | ||
| PCT/JP2017/045731 WO2018117153A1 (en) | 2016-12-21 | 2017-12-20 | Crystalline forms of a janus kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022207814A Division JP2023024729A (ja) | 2016-12-21 | 2022-12-26 | ヤヌスキナーゼ阻害剤の結晶形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502224A JP2020502224A (ja) | 2020-01-23 |
| JP2020502224A5 true JP2020502224A5 (enExample) | 2021-02-04 |
Family
ID=60991475
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533666A Pending JP2020502224A (ja) | 2016-12-21 | 2017-12-20 | ヤヌスキナーゼ阻害剤の結晶形 |
| JP2022207814A Pending JP2023024729A (ja) | 2016-12-21 | 2022-12-26 | ヤヌスキナーゼ阻害剤の結晶形 |
| JP2024134769A Pending JP2024161449A (ja) | 2016-12-21 | 2024-08-13 | ヤヌスキナーゼ阻害剤の結晶形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022207814A Pending JP2023024729A (ja) | 2016-12-21 | 2022-12-26 | ヤヌスキナーゼ阻害剤の結晶形 |
| JP2024134769A Pending JP2024161449A (ja) | 2016-12-21 | 2024-08-13 | ヤヌスキナーゼ阻害剤の結晶形 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11339181B2 (enExample) |
| EP (1) | EP3559003B1 (enExample) |
| JP (3) | JP2020502224A (enExample) |
| KR (1) | KR102788829B1 (enExample) |
| CN (2) | CN121045220A (enExample) |
| AU (1) | AU2017380213B2 (enExample) |
| BR (1) | BR112019012210A2 (enExample) |
| CA (1) | CA3044771A1 (enExample) |
| ES (1) | ES2926986T3 (enExample) |
| IL (1) | IL267393B2 (enExample) |
| MX (1) | MX386181B (enExample) |
| TW (1) | TWI822666B (enExample) |
| WO (1) | WO2018117153A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI854815B (zh) | 2016-12-21 | 2024-09-01 | 日商日本煙草產業股份有限公司 | 7H-吡咯并[2,3-d]嘧啶衍生物的製造方法及其合成中間體 |
| EP4011450A4 (en) * | 2019-08-07 | 2023-08-09 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic composition for promoting tear secretion |
| CN111606929B (zh) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | 德高替尼的制备方法 |
| JP7807247B2 (ja) * | 2021-02-05 | 2026-01-27 | ロート製薬株式会社 | シェーグレン症候群治療剤 |
| KR20240027044A (ko) * | 2021-07-30 | 2024-02-29 | 일라이 릴리 앤드 캄파니 | 바리시티닙을 사용한 손 습진의 치료 |
| IL322047A (en) | 2023-02-28 | 2025-09-01 | Assia Chem Ind Ltd | Solid forms of dalgocitinib and processes for their preparation |
| WO2024225445A1 (en) * | 2023-04-27 | 2024-10-31 | Japan Tobacco Inc. | Crystalline form of delgocitinib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009500666A (ja) * | 2005-07-07 | 2009-01-08 | トムソン ライセンシング | 対応スタンドを備えたフラット画面ディスプレイシステム |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP3643312A1 (en) * | 2009-05-22 | 2020-04-29 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| GB201004200D0 (en) * | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| JP6427497B2 (ja) * | 2013-10-21 | 2018-11-21 | 日本たばこ産業株式会社 | 眼疾患の治療剤又は予防剤 |
| TWI729990B (zh) * | 2015-07-07 | 2021-06-11 | 日商日本煙草產業股份有限公司 | 7H-吡咯并[2,3-d]嘧啶衍生物的製造方法及其中間物 |
-
2017
- 2017-12-20 KR KR1020197017128A patent/KR102788829B1/ko active Active
- 2017-12-20 CA CA3044771A patent/CA3044771A1/en active Pending
- 2017-12-20 WO PCT/JP2017/045731 patent/WO2018117153A1/en not_active Ceased
- 2017-12-20 EP EP17829724.8A patent/EP3559003B1/en active Active
- 2017-12-20 CN CN202511159370.4A patent/CN121045220A/zh active Pending
- 2017-12-20 ES ES17829724T patent/ES2926986T3/es active Active
- 2017-12-20 CN CN201780086980.3A patent/CN110325536A/zh active Pending
- 2017-12-20 US US16/470,854 patent/US11339181B2/en active Active
- 2017-12-20 BR BR112019012210-9A patent/BR112019012210A2/pt not_active Application Discontinuation
- 2017-12-20 MX MX2019007462A patent/MX386181B/es unknown
- 2017-12-20 JP JP2019533666A patent/JP2020502224A/ja active Pending
- 2017-12-20 TW TW106144831A patent/TWI822666B/zh active
- 2017-12-20 AU AU2017380213A patent/AU2017380213B2/en active Active
-
2019
- 2019-06-16 IL IL267393A patent/IL267393B2/en unknown
-
2022
- 2022-12-26 JP JP2022207814A patent/JP2023024729A/ja active Pending
-
2024
- 2024-08-13 JP JP2024134769A patent/JP2024161449A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502224A5 (enExample) | ||
| AU2022201072A1 (en) | Compositions and methods for inhibiting arginase activity | |
| CA2800541C (en) | Soluble guanylate cyclase activators | |
| TW201100426A (en) | New compounds for the treatment of CNS disorders | |
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| ES2351958T3 (es) | 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis. | |
| JP2018035160A5 (enExample) | ||
| CL2008002184A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension pulmonar, osteoporosis, artritis, entre otras. | |
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| JP2011523412A5 (enExample) | ||
| JP2018514544A (ja) | Ｒｓｖ抗ウイルス性ピラゾロおよびトリアゾロピリミジン化合物 | |
| ME02612B (me) | Tenofovir alafenamid hemifumarat | |
| JP2009502780A5 (enExample) | ||
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| TW201209026A (en) | Process for the preparation of pleuromutilins | |
| CN102131809A (zh) | 三环吡唑并吡啶激酶抑制剂 | |
| CA2776342C (en) | Agomelatine and pharmaceutical compositions thereof | |
| WO2010059922A1 (en) | Pyrrolidine carboxamide compounds | |
| JP2010514725A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| PH12017501690A1 (en) | Crystal of 3,5-disubstituted benzene alkynyl compound | |
| TN2012000132A1 (en) | N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes | |
| JP2015522037A5 (enExample) | ||
| JP2011527687A5 (enExample) | ||
| JPWO2021033729A5 (enExample) |